F-1/A: Anew Health IPO Faces Going Concern Doubts Amid Profit Plunge

Anew Health Limited, a Hong Kong-based pain management provider, is pursuing an initial public offering on Nasdaq despite a 53% net income decrease and auditor-raised substantial doubt about its ability to continue as a going concern.

Summary

• Anew Health Limited, a Cayman Islands holding company operating in Hong Kong through its subsidiaries VG Zenith and Victor Zenith, is conducting an initial public offering of 1,800,000 ordinary shares.
• The expected initial public offering price is between US$4.00 and US$6.00 per Ordinary Share, with estimated net proceeds of approximately US$4.75 million at the minimum price.
• The company's total revenue for the year ended March 31, 2025, was approximately US$40.0 million, a 1.9% decrease from US$40.8 million in the prior year.
• Net income significantly decreased by 53%, from US$11.7 million in FY2024 to US$5.5 million in FY2025, primarily due to increased cost of revenue, marketing, and general and administrative expenses.
• As of March 31, 2025, the company had a working capital deficit of US$7,827,815, leading its auditor to express substantial doubt about its ability to continue as a going concern.
• Anew Health offers non-surgical, non-invasive, and non-pharmacological pain management and functional enhancement therapies under its ANKH brand, combining Traditional Chinese Medicine (TCM) wisdom with energy-based treatment devices.
• The company operates three service centers in Hong Kong and sells private-label topical use and dietary supplement products.
• Post-IPO, AW Ocean Limited, the controlling shareholder, will own 96.53% of the voting power, making Anew Health a controlled company under Nasdaq rules, though it does not currently intend to rely on the exemption.
• The company is subject to significant regulatory and political risks associated with operating in Hong Kong, including potential intervention from the PRC government and uncertainties regarding data security laws.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant decline in net income (53%), a persistent working capital deficit, and the auditor's explicit 'going concern' warning. While there are growth strategies and market opportunities, the immediate financial health and operational risks, particularly regulatory uncertainties in Hong Kong and China, overshadow the positives.

Positives

• Anew Health has over 16 years of experience in pain management and functional enhancement under its reputable ANKH brand, which is well-recognized in Hong Kong.
• The company's RDS+ approach combines Traditional Chinese Medicine with modern energy-based treatment devices, offering non-surgical, non-invasive, and non-pharmacological therapies.
• An internal customer survey from April 2023 to March 2024 showed 81.7% client satisfaction with services and 69.4% reported reduction/relief of pain symptoms.
• The company served 10,039 clients in FY2025, an increase from 8,692 in FY2024, with average annual client spending increasing by 3.2% to US$6,478.
• Anew Health has a visionary senior management team with extensive industry experience, supported by qualified professionals including physiotherapists, nutritionists, and Chinese Medicine Practitioners.
• The company maintains rigorous service standards, quality control, and training systems, resulting in a low refund rate of 0.86% of contracted sales in FY2025.
• Growth strategies include expanding the customer base and service center network in Hong Kong, enhancing brand awareness, and strategically expanding into selected global markets (e.g., Singapore, Malaysia, Japan, South Korea, Canada, and the United States).
• Plans to establish a specialized research and development department in Q1 2025 to develop energy-based treatment devices for professional and consumer retail markets, with prototypes expected in early 2026 and market readiness by end of 2026.

Negatives

• Net income decreased significantly by 53%, from US$11.7 million in FY2024 to US$5.5 million in FY2025.
• The company reported a working capital deficit of US$7,827,815 as of March 31, 2025, and US$7,765,739 as of March 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• Cost of revenue increased by 16.8% (US$1.9 million) in FY2025, primarily due to higher personnel costs and increased headcount.
• General and administrative expenses increased by 46.8% (US$3.6 million) in FY2025, driven by senior management compensation, a one-off discretionary bonus of US$1.28 million, and costs for a new treatment center.
• Selling and marketing expenses increased by 16.8% (US$1.1 million) in FY2025.
• The company relies on a single geographical market (Hong Kong), making it vulnerable to adverse economic, social, and political conditions in the region.
• Management lacks experience in managing a U.S. public company and complying with associated laws, which could adversely affect business operations.
• The company does not maintain product liability insurance, exposing it to substantial financial and reputational damage from potential claims or recalls.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to working capital deficit.
• Significant variability in operating results and profitability due to increased operating expenses and cost of revenue.
• Risk of unfavorable publicity or consumer perception impacting reputation and demand for services.
• Exposure to customer complaints, claims, and legal proceedings, potentially leading to significant costs and reputational damage.
• Failure to maintain the quality of equipment, treatment devices, supplies, and products, leading to liabilities and reputational harm.
• Reliance on third-party suppliers, including limited source suppliers, for products and treatment devices, risking supply disruptions and increased costs.
• Lack of long-term supply agreements with treatment device suppliers, leading to potential price fluctuations or unavailability.
• Inherent risks related to product liability claims or product recalls for topical use and dietary supplement products, with no product liability insurance coverage.
• Evolving regulatory requirements in Hong Kong, with potential penalties for non-compliance or significant costs for changes in business practices.
• Inability to hire and retain qualified personnel (consultants, therapists, management) to support growth, affecting service quality and business strategy.
• Intense competition in the pain management and health services industry, potentially leading to market share loss and reduced profitability.
• Market for products and services may not grow as expected, adversely affecting business and operating results.
• Introduction of disruptive technological breakthroughs (energy-based, pharmaceutical) could present challenges or render existing products/services obsolete.
• Newly opened and acquired service centers may not achieve anticipated operating results, impacting overall profitability.
• Dependence on certain key personnel, with loss of services potentially disrupting operations and delaying strategies.
• Cybersecurity risks, breaches, and other disruptions could compromise customer data, damage reputation, and expose the company to liability.
• Occurrence of force majeure events (natural disasters, pandemics, political events) could disrupt operations and financial performance.
• Potential for increased rent or non-renewal of lease agreements, affecting operations and financial condition.
• PRC government may exercise significant direct oversight and discretion over Hong Kong operations, potentially changing business value or operations.
• Uncertainties regarding future PRC approvals for U.S. listings and data security laws, potentially hindering ability to offer securities.
• Enforcement of laws and regulations in the PRC and Hong Kong can change quickly, limiting legal protections.
• Impact of the Hong Kong National Security Law and HKAA on Hong Kong subsidiaries and business operations.
• Political risks associated with conducting business in Hong Kong, including changes in political arrangements between PRC and Hong Kong.
• Changes in currency conversion rates between HKD and USD may affect investment value.
• Corporate actions substantially controlled by AW Ocean Limited (96.53% voting power), potentially depriving other shareholders of premium opportunities.
• Reliance on dividends from subsidiaries to fund cash and financing requirements, with potential restrictions on cash transfers by the PRC government.
• Difficulties in enforcing foreign civil liabilities in the Cayman Islands and Hong Kong against the company or its directors/officers.
• Limited ability to protect interests through U.S. courts due to Cayman Islands incorporation.
• Potential delisting from Nasdaq under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB is unable to inspect auditors for two consecutive years.
• No prior public market for Ordinary Shares, risking inability to resell at or above IPO price.
• Extreme stock price volatility unrelated to operating performance, making valuation difficult.
• Thinly traded Ordinary Shares, potentially making it difficult to sell shares.
• Immediate and substantial dilution for new investors purchasing Ordinary Shares in the offering.
• Sale or availability of substantial amounts of Ordinary Shares in the public market could adversely affect market price.
• Lack of research or negative reports from securities analysts could cause stock price and trading volume to decline.
• Broad discretion in the use of net proceeds from the offering, which may not be used effectively.
• Nasdaq may apply additional and more stringent listing criteria due to small public offering and high insider ownership.
• Loss of foreign private issuer status could result in significant additional costs and expenses.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Reliance on price appreciation for investment return, as dividend distribution is at board's discretion and not planned for the foreseeable future.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. investors.

Future Outlook

The company intends to drive organic growth by expanding its customer base and service center network in Hong Kong, enhancing brand awareness, and strategically expanding into selected global markets such as Singapore, Malaysia, Japan, South Korea, Canada, and the United States. It plans to maintain and enhance the professional expertise of its frontline staff, develop and broaden its treatment services and product offerings, and substantially enhance its research and development capabilities. A specialized R&D department is planned for Q1 2025 to develop energy-based treatment devices for professional use and portable at-home devices for the consumer retail market, with prototypes expected in early 2026 and market readiness by the end of 2026.

Management Comments

• We believe that our professional services, proven approach to pain management, and capability to offer a broad range of treatment services and products have enabled us to offer our clients distinguished experience at our service centers.
• Our RDS+ approach to pain management and function enhancement therapies have been refined through over sixteen years of operation and proven by more than 400,000 services provided to our customers whom we have served.
• The ANKH brand has become a well-recognized, trustworthy, and reliable icon in Hong Kong for the provision of quality pain management and health services.
• We believe that our current cash and cash equivalents, anticipated cash flow from operations, available credit facilities, and the proceeds from this offering will be sufficient to meet our anticipated cash needs for at least the next 12 months.
• We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future.

Industry Context

The non-pharmacological pain management market in Hong Kong is expanding due to an aging population, increasing awareness of chronic pain, and a desire for non-pharmaceutical options. The market is projected to grow at an 8.7% CAGR in sales value from HKD 6,674 million in 2023 to HKD 7,882 million in 2025. Post-COVID-19 conditions also contribute to demand. The industry is competitive and fragmented, with a shift towards more pain-focused models and multidisciplinary management. There is increasing scrutiny on non-pharmacological treatment selling skills and high-priced prepaid packages, potentially leading to more stringent regulatory frameworks that could benefit large-scale providers.

Comparison to Industry Standards

• Anew Health is ranked No. 3 in terms of average spending per customer and No. 4 in customer experience trails within the non-pharmacological pain management services market in Hong Kong, according to Migo research.
• The average annual spending of each client at Anew Health's service centers was approximately US$6,478 in FY2025, compared to HK$49,124 (approx. US$6,300) average spending for premium pain management brands in Hong Kong in 2024, indicating competitive pricing or service value.
• The non-pharmacological pain management market in Hong Kong is characterized by local chain centers, with Anew Health competing against providers like NYMG Pain Center (25 branches), New Hope Medical (2 branches), Hong Kong Medical Pain Management Association (2 branches), and HK Pain Tech Institute (5 branches).
• The industry is capital-intensive, requiring significant investment in cutting-edge devices and prime locations, which Anew Health addresses through its three well-equipped service centers and plans for further expansion.
• The market faces challenges from limited supply of experienced Chinese medicine practitioners and therapists, which Anew Health mitigates by employing 8 full-time Chinese Medicine Practitioners and 95 trained therapists, and providing extensive in-house training.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company has not been involved in any legal proceedings, investigations, or claims, nor is it aware of any pending or threatened litigation, arbitration, or other claims that would have a material adverse impact on its operations, financial position, and reputation.
• The company has not been involved in any incidents of material noncompliance with applicable laws and regulations in Hong Kong.

Related Party Transactions

• On September 27, 2024, Anew Health declared a dividend of US$10,740,727 to AW Ocean Limited (Controlling Shareholder) to partially set off amounts due from Mr. Ka Wai Victor, MO (Director, CEO, and ultimate shareholder).
• As of March 31, 2024, US$1,073,723 was due from Mr. Ka Wai Victor, MO, representing an unsecured, interest-free personal loan for investment purposes, which was fully repaid in cash on November 7, 2024.
• As of March 31, 2025, US$139,968 was due to Mr. Ka Wai Victor, MO, representing operational expenses paid by him on behalf of VG Zenith, unsecured and interest-free.
• For FY2025, US$3,436,112 was paid as compensation to directors and executive officers by Operating Subsidiaries, including US$2,526,629 to Mr. Ka Wai Victor, MO and US$603,105 to Ms. Sum Lok, CHEUNG.
• For FY2024, US$1,008,103 was paid as compensation to directors and executive officers by Operating Subsidiaries, including US$563,863 to Mr. Ka Wai Victor, MO and US$236,689 to Ms. Sum Lok, CHEUNG.

Stakeholder Impact

• **Shareholders (Existing & New):** Will experience significant dilution from the IPO. Existing shareholders (AW Ocean Limited) will retain majority control (96.53% voting power). New investors face high risk, including potential loss of entire investment, due to the company's going concern warning and stock price volatility.
• **Employees:** Increased personnel costs and headcount indicate continued investment in staff, but the company's financial instability (going concern) could pose future risks to job security or compensation.
• **Customers:** Continued expansion of service centers and R&D into new treatments and at-home devices aims to enhance service offerings and accessibility. However, any adverse publicity or failure to maintain service quality could erode trust.
• **Suppliers:** Reliance on third-party suppliers, especially for treatment devices and private-label products, means their performance and compliance are critical. Any disruptions could impact service delivery.
• **Creditors:** The working capital deficit and going concern warning indicate increased risk for creditors, potentially affecting the company's ability to secure additional financing on favorable terms.

Next Steps

• Listing Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Establishing a new service center in Hong Kong (one opened in Causeway Bay in June 2025).
• Establishing new service centers in selected international markets (Singapore, Malaysia, Japan, South Korea, Canada, United States).
• Enhancing and upgrading information technology systems and infrastructure.
• Establishing a specialized research and development department in Q1 2025.
• Developing and commercializing energy-based treatment devices for professional use (prototype by early 2026, market ready by end of 2026).
• Developing and commercializing portable home-use treatment devices for the consumer retail market.
• Diversifying topical use and dietary supplement product lines for retail and online sales.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with a 53% drop in net income and a persistent working capital deficit leading the auditor to express 'substantial doubt about the company's ability to continue as a going concern.' This fundamental financial instability, coupled with significant regulatory and political risks associated with operating solely in Hong Kong under potential PRC oversight, makes the investment extremely speculative. While growth strategies are outlined, the immediate and severe financial deterioration, high insider ownership, and lack of product liability insurance present overwhelming risks that far outweigh any potential upside. Investors should avoid this offering.

Keywords

Pain Management, Health Services, Hong Kong, IPO, Nasdaq, SEC Filing, Traditional Chinese Medicine, TCM, Energy-based Treatment, Wellness, Healthcare Products, Going Concern, Working Capital Deficit, PRC Regulatory Risk, HFCAA, Foreign Private Issuer, Controlled Company, Share Dilution, ANKH Brand, RDS+ Approach, Medical Devices, Dietary Supplements, Corporate Governance, Financial Performance